XORTX Therapeutics Inc. (XRTX)
NASDAQ
$1.70−$0.0200 (−1.16%) on the dayAs of the close; data may be delayed.
XRTX price, last 12 months
Key stats
- Previous close
- $1.72
- Open
- $1.72
- Day range
- $1.61 – $1.82
- 52-week range
- $1.59 – $7.05
- Volume
- 44.2K
- Avg volume (20 days)
- 688.8K
- Market cap
- $3.1M
Performance
1W−11.5%
1M−23.4%
3M−22.4%
6M−1.5%
YTD−39.5%
1Y−60.6%
vs S&P 500, 1Y−77.4 pts
Technicals and fundamentals
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
- Listed on
- NASDAQ
- Market cap
- $3.1M